Romiplostim Elicits High Responses in Pediatric Immune Thrombocytopenia

Michael D. Tarantino, MD, PDSA Medical Advisory Board
Michael D. Tarantino, MD, PDSA Medical Advisory Board

Most pediatric patients with immune thrombocytopenia (ITP) had rapid and durable platelet responses when treated with the thrombopoietin fusion protein analog romiplostim (Nplate), according to integrated data from 5 clinical trials that were presented at the 2018 ASH Annual Meeting.

Nearly 90% of 282 evaluable patients had platelet responses, which occurred after a median treatment duration of 6 weeks. Patients remained in response for a median of 76% of months during follow-up.

- From OncLive

Read More

back to top
Charity Navigator
GuideStar Seal
NORD Member Badge
THSNA logo
THSNA Summit 2024
April 3-6th
https://www.thsna.org/2024